BOOSTER
Phase 2 Completed
155 enrolled 23 charts
Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
Phase 2 Completed
90 enrolled 6 charts
Reolysin in Combination With FOLFOX6 and Bevacizumab or FOLFOX6 and Bevacizumab Alone in Metastatic Colorectal Cancer
Phase 2 Completed
109 enrolled 13 charts
BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
70 enrolled 10 charts
Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer
Phase 2 Completed
247 enrolled 10 charts
Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
Phase 3 Completed
722 enrolled
Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer
Phase 2 Completed
122 enrolled
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Phase 2 Completed
182 enrolled 19 charts
BELIEF
Phase 2 Completed
109 enrolled 20 charts
A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer
Phase 3 Completed
1,613 enrolled
Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
Phase 2 Completed
150 enrolled 11 charts
Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer
Phase 2 Completed
105 enrolled 17 charts
Bevacizumab and Lomustine for Recurrent GBM
Phase 3 Completed
592 enrolled
S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma
Phase 2 Completed
84 enrolled 15 charts
S0636: Erlotinib and Bevacizumab in Never-Smokers With Stage IIIB or Stage IV Primary Non-Small Cell Lung Cancer
Phase 2 Completed
89 enrolled 11 charts
Stop&Go
Phase 3 Completed
420 enrolled
TC Avastin. ICORG 08-10, V6
Phase NA Completed
106 enrolled
TAVAREC
Phase 2 Completed
155 enrolled
Biomarker Study of Blood Samples From Patients With Non-Small Cell Lung Cancer Treated With Carboplatin and Paclitaxel With or Without Bevacizumab
Completed
90 enrolled
Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel
Completed
180 enrolled
Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer
Phase 1 Completed
13 enrolled
ABCSG 32
Phase 2 Completed
100 enrolled
Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy
Phase 2 Completed
25 enrolled
Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Solid Tumors
Phase 1 Completed
20 enrolled
The MAX Study: Mitomycin C, Avastin and Xeloda in Patients With Untreated Metastatic Colorectal Cancer
Phase 2/3 Completed
333 enrolled